Cardiorenai interactions: ciinicai indications and roie in pathogenesis of cardiovascular and renal diseases


Cite item

Full Text

References

  1. Тареев Е. М. Нефриты. М.: Медгиз; 1958.
  2. Jessup M., Brozena S. Heart failure, N. Engl. J. Med. 2003; 348: 2007-2018.
  3. Wolf G. Angiotensin II: a pivotal factor in the progression of renal disease. Nephrol. Dial. Transplant. 1999; 14 (suppl. 1): 42-44.
  4. Garg R., Yusuf S. For the Collaborative Group on ACE Inhibitor Trials. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. J. A. M. A. 1995; 273: 1450-1456.
  5. Ruggenenti P., Schiepatti A., Remuzzi G. Progression, remission, regression of chronic renal diseases. Lancet 2001; 357: 1601- 1618.
  6. Komajada M. Are angiotensin II receptor blockers indicated in chronic heart failure? Heart 2002; 87: 1-2.
  7. Wong M., Staszewsky L., Latini R. et al. Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiography study. J. Am. Coll. Cardiol. 2002; 40: 970- 975.
  8. Yusuf S., Pfeffer M. A., Swedberg A. et al. Effects of candesartan in patients with chronic heart failure and preserved leftventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003; 362: 777-781.
  9. Brenner B. M., Cooper M. E., De Zeeuw D. et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N. Engl. J. Med. 2001; 345: 861-869.
  10. Parving H. H., Lenhert H., Brochner-Mortensen J. et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N. Engl. J. Med. 2001; 345: 870-878.
  11. Nakao N., Yoshimura A., Morita M. et al. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomized controlled trial. Lancet 2003; 361: 117-124.
  12. McMurray J. J. V., Ostegren J., Swedberg K. et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-convertingenzyme inhibitors: the CHARM-added trial. Lancet 2003; 362: 767-771.
  13. Struthers A. D. Impact of aldosterone on vascular pathophysiology. Congest. Heart Fail. 2002; 8: 18-22.
  14. Pitt В., Zannad F., Remme W. J. et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N. Engl. J. Med. 1999; 341: 709-717.
  15. Pitt В., Remme W., Zannad F. et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N. Engl. J. Med. 2003; 348: 1309-1321.
  16. De Bold A. J., Borenstein H. В., Veress А. Т., Sonnenberg H. A. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. Life Sci. 1981; 28: 89-94.
  17. Елисеев О. М. Натрийуретические пептиды. Эволюция знаний. Тер. арх. 2003; 9: 40-46.
  18. Хирманов В. Н. Предсердный натрийуретический гормон. Тер. арх. 1987; 11: 142-147.
  19. Troughton R. W., Frampton С. М., Yandle Т. G. et al. Treatment of heart failure guided by plasma aminoterminal peptide (N-BNP) concentrations. Lancet 2000; 355: 1126-1130.
  20. Nagaya N., Nishikimi Т., Goto Y. et al. Plasma brain natriuretic peptide is a biochemical marker for the prediction of progressive ventricular remodeling after acute myocardial infarction. Am. Heart J. 1998; 135: 21-28.
  21. Latini R., Masson S., Anand I. et al. Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure. The Valsartan Heart Failure Trial (Val-HeFT). Circulation 2002; 106: 2454-2458.
  22. Anand I., Fischer L., Chiang Y.-T. et al. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (ValHeFT). Circulation 2003; 107: 1278-1283.
  23. Colucci W. S., Elkayam U., Horton D. P. et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. N. Engl. J. Med. 2000; 343: 246-253.
  24. Aronson D., Burger A. J. Intravenous nesiritide (human b-type natriuretic peptide) reduces plasma endothelin-l levels in patients with decompensated heart failure. Am. J. Cardiol. 2002; 15:435-438.
  25. Meyer M., Pfarr E., Schrimer G. et al. Therapeutic use of the natriuretic peptide ularitide in acute renal failure. Ren. Fail. 1999; 21: 85-100.
  26. McClean D. R., Ikram H., Garlick A. H. et al. The clinical, cardiac, renal, arterial and neurohormonal effects of omapatrilat, a vasopeptidase inhibitor, in patients with chronic heart failure. J. Am. Coll. Cardiol. 2000; 36: 479-486.
  27. Cao Z., Burrell L. M., Tikkanen I. et al. Vasopeptidase inhibition attenuates the progression of renal injury in subtotal nephrectomized rats. Kidney Int. 2001; 60: 715-721.
  28. Rouleau J. L., Pfeffer M. A., Stewart D. J. et al. Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure IMPRESS randomized trial. Lancet 2000; 356: 615-620.
  29. Baigent C., Burbury K., Wheeler D. Premature cardiovascular disease in chronic renal failure. Lancet 2000; 356: 147-152.
  30. Мухин Н. А., Шоничев Д. Г., Балкаров И. М. и др. Формирование артериальной гипертонии при уратном тубулоинтерстициальном поражении почек. Тер. арх. 1999; 6: 12- 24.
  31. Мухин Н. А., Балкаров И. М., Моисеев С. В. и др. Урикозурическое действие лозартана. Клин, фармакол. и тер. 2003; 5: 55-58.
  32. Моисеев В. С., Кобалава Ж. Д. Кардиоренальный синдром (почечный фактор и повышение риска сердечно-сосудистых заболеваний). Клин, фармакол. и тер. 2003; 3: 16-18.
  33. Кобалава Ж. Д., Котовская Ю. В., Чистяков Д. А. и др. Клинико-генетические детерминанты гипертрофии левого желудочка у больных эссенциальной гипертонией. Кардиология 2002; 7: 39-44.
  34. Goldberg R., Burchjiel С., Benfante С. et al. Lifestyle and biological factors associated with atherosclerotic disease in middle-aged men: 20-year findings from the Honolulu Heart Program. Arch. Intern. Med. 1995; 155: 686-694.
  35. Levine W., Dyer A., Shekelle R. et al. Serum uric acid and 11,5 mortality of middle-aged women: findings of the Chicago Heart Association detection project in industry. J. Clin. Epi miol. 1989; 42: 257-267.
  36. Alderman M. H., Cohen H., Madhavan S., Kivlighn S. Ser uric acid and cardiovascular events in successfully treated 1 pertensive patients. Hypertension 1999; 34: 144-150.
  37. Verdecchia P., Schillaci G., Reboldi G.-P. Relation between ram uric acid and risk of cardiovascular disease in essential 1 pertension. The PIUMA Study Hypertension 2000; 36: 107; 1078.
  38. Franse L., Pahor M., Di Bari M. et al. Serum uric acid, diui tic treatment and risk of cardiovascular events in the Systo Hypertension in the Elderly Program (SHEP). J. Hypertei 2000; 18: 1149-1154.
  39. Farquharson С. A. J., Butler R., Hill A. et al. Allopurinol it proves endothelial dysfunction in chronic heart failure. Circ lation2002; 106:221-226.
  40. Jones С. A., Francis M. E., Eberhardt M. S. et al. Microalbi minuria in the US population: third National Health and Ni trition Examination Survey. Am. J. Kidney Dis. 2002; 3 445-459.
  41. Diercks G. F., van Boven A. J., Hillege H. L. et al. Microalbt minuria is independently associated with ischaemic electroca; diographic abnormalities in a large non-diabetic populatioi The PREVEND (Prevention of REnal and Vascular ENdstag Disease) study. Eur. Heart J. 2000; 21: 1922-1927.
  42. Hamano K., Iwano M., Akai Y. et al. Expression of glomerate plasminogen activator inhibitor type 1 in glomerulonephriti: Am. J. Kidney Dis. 2002; 39: 695-705.
  43. Мухин Н. А., Козловская Л. В., Кутырина И. М. и др. Про теинурическое ремоделирование тубуло-интерстиция мишень нефропротективной стратегии при хронически заболеваниях почек. Тер. арх. 2002; 6: 5-11.
  44. Foley R. N., Parfrey P. S., Harnett J. D. et al. The impact о anemia on cardiomyopathy, morbidity and mortality in end stage renal disease. Am. J. Kidney Dis. 1996; 28: 53-61.
  45. Silverberg D. S., Wexler D., Blum M. et al. The use of subcutaneous erythropoietin and intravenous iron for the treatment о the anaemia of severe, resistant congestive heart failure improves cardiac and renal function, functional cardiac class, anc markedly reduces hospitalization. J. Am. Coll. Cardiol. 2000 35: 1737-1744.
  46. McClellan W., Flanders W. D., Langston R. D. et al. Anemia and renal insufficiency are independent risk factors for death among patients with congestive heart failure admitted to community hospitals: a population-based study. J. Am. Soc. Nephrol. 2002; 13: 1928-1936.
  47. Sarnak M. J., Tighiouart H., Manjunath G. et al. Anemia as a risk factor for cardiovascular disease in the Atherosclerosis Risk in Communities (ARIC) study. J. Am. Coll. Cardiol. 2002; 40: 27-33.
  48. Silverberg D. S., Wexler D., Iaina A. The importance of anemia and its correction in the management of severe congestive heart failure. Eur. J. Heart Fail. 2002; 4: 681-686.
  49. Alcazar J. M., Rodicio J. L. Ischemic nephropathy: clinical characteristics and treatment. Am. J. Kidnev Dis. 2000- 36' 883-893.
  50. Мухин Н. А., Козловская Л. В., Кутырина И. М. и др. Ишемическая болезнь почек. Тер. арх. 2003; 6: 5-12.
  51. Johansson M., Herlitz H., Jensen G. et al. Increased cardiovascular mortality in hypertensive patients with renal artery stenosis. Relation to sympathetic activation, renal function and treatment regimens. J. Hypertens. 1999; 17: 1743-1750.
  52. Чазов Е. И. Кардиология на стыке веков. Врач 2000; 24-6.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2004 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies